Base de dados : MEDLINE
Pesquisa : C25.775 [Categoria DeCS]
Referências encontradas : 84857 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 8486 ir para página                         

  1 / 84857 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29437654
[Au] Autor:Woolf SH; Aron L
[Ad] Endereço:Center on Society and Health, Virginia Commonwealth University, 830 East Main Street, Suite 5035, Richmond, Virginia 23298-0212, USA steven.woolf@vcuhealth.org.
[Ti] Título:Failing health of the United States.
[So] Source:BMJ;360:k496, 2018 02 07.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Indicadores Básicos de Saúde
Expectativa de Vida
[Mh] Termos MeSH secundário: Feminino
Política de Saúde
Seres Humanos
Masculino
Fatores de Risco
Transtornos Relacionados ao Uso de Substâncias/etnologia
Transtornos Relacionados ao Uso de Substâncias/mortalidade
Suicídio/etnologia
Suicídio/estatística & dados numéricos
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:EDITORIAL
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180214
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k496


  2 / 84857 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455636
[Au] Autor:Duprey EB; Oshri A; Caughy MO
[Ad] Endereço:The Youth Development Institute, Human Development and Family Science, University of Georgia, Athens, GA, USA. erinn.duprey@uga.edu.
[Ti] Título:Childhood Neglect, Internalizing Symptoms and Adolescent Substance Use: Does the Neighborhood Context Matter?
[So] Source:J Youth Adolesc;46(7):1582-1597, 2017 Jul.
[Is] ISSN:1573-6601
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Childhood neglect is associated with risk behaviors in adolescence, including substance use. There is evidence that internalizing behaviors may serve as a mechanism linking childhood neglect and substance use; however, further research is needed to examine this developmental pathway. According to developmental and ecological approaches, the neighborhood context and the developmental timing of maltreatment should both be considered when examining the sequelae of childhood neglect. Hence, the present study uses a longitudinal sample of youth (N = 965, 49.1% female, 59.2% African-American) to examine the influence of timing in the relationship between childhood neglect and adolescent psychopathology, and to examine the indirect effects of child neglect on substance use via internalizing symptoms in adolescence. Furthermore, the role of neighborhood disorder in this indirect effect was tested. Five data collection time points were used: Time 1(M = 4.557, SD = .701), Time 2 (M = 6.422, SD = .518), Time 3 (M = 12.370, SD = .443), Time 4 (M = 14.359, SD = .452), and Time 5 (M = 16.316, SD = .615). The findings showed that internalizing problems mediated the link between the severity of neglect in early childhood and adolescent substance use, and this pathway was moderated by neighborhood disorder. These results have implications for preventative interventions aimed toward reducing substance use for at-risk adolescents.
[Mh] Termos MeSH primário: Maus-Tratos Infantis/diagnóstico
Maus-Tratos Infantis/psicologia
Controle Interno-Externo
Distribuição Espacial da População
Transtornos Relacionados ao Uso de Substâncias/diagnóstico
Transtornos Relacionados ao Uso de Substâncias/psicologia
[Mh] Termos MeSH secundário: Adolescente
Criança
Maus-Tratos Infantis/estatística & dados numéricos
Pré-Escolar
Ajustamento Emocional
Feminino
Seres Humanos
Acontecimentos que Mudam a Vida
Masculino
Distribuição Espacial da População/estatística & dados numéricos
Assunção de Riscos
Mudança Social
Estatística como Assunto
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE
[do] DOI:10.1007/s10964-017-0672-x


  3 / 84857 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29179817
[Au] Autor:Mahmoud KF; Finnell D; Savage CL; Puskar KR; Mitchell AM
[Ad] Endereço:University of Pittsburgh School of Nursing, 3500 Victoria Street, 415 Victoria Building, Pittsburgh, PA 15261, USA. Electronic address: kfm22@pitt.edu.
[Ti] Título:A Concept Analysis of Substance Misuse to Inform Contemporary Terminology.
[So] Source:Arch Psychiatr Nurs;31(6):532-540, 2017 12.
[Is] ISSN:1532-8228
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Previous diagnostic categories of substance abuse and dependence have given way to the current view that substance use disorders occur on a continuum with a broad range of severity. This current view is featured in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM V). In recognizing the role of stigma in preventing persons from seeking substance use treatment, advocates have called attention that particular terminology can fuel such stigma. To mitigate the negative effects of such stigmatizing language, the International Society of Addiction Journal Editors (ISAJE) recommends against using previously-used and possibly pejorative terminology for substance abuse and dependence, unless a particular scientific justification exists. The purpose of this paper is to: (1) present a concept analysis of the term substance misuse and (2) recommend an alternate term for substance misuse that is neither pejorative nor inadvertently stigmatizing: at-risk substance use.
[Mh] Termos MeSH primário: Manual Diagnóstico e Estatístico de Transtornos Mentais
Transtornos Relacionados ao Uso de Substâncias/classificação
Terminologia como Assunto
[Mh] Termos MeSH secundário: Seres Humanos
Índice de Gravidade de Doença
Estigma Social
Transtornos Relacionados ao Uso de Substâncias/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE


  4 / 84857 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29355909
[Au] Autor:Temmingh HS; Williams T; Siegfried N; Stein DJ
[Ad] Endereço:Department of Psychiatry and Mental Health, University of Cape Town, Valkenberg Hospital, Private Bage X1, Cape Town, Western Cape, South Africa, 7935.
[Ti] Título:Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
[So] Source:Cochrane Database Syst Rev;1:CD011057, 2018 Jan 22.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substance use disorders (dual diagnosis). Dual diagnosis can have an adverse effect on treatment and prognosis of SMI. OBJECTIVES: To evaluate the effects of risperidone compared to treatment with other antipsychotics (first-generation and other second-generation antipsychotics) used in people with serious mental illness and co-occurring substance misuse. SEARCH METHODS: On 6 January 2016 and 9 October 2017, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (including trial registers). SELECTION CRITERIA: We selected randomised trials of risperidone versus any other antipsychotic in people with SMI and substance abuse (dual diagnosis). We included trials meeting our inclusion criteria and reporting useable data. We excluded trials that either did not meet our inclusion criteria or met our inclusion criteria but did not report any useable data. DATA COLLECTION AND ANALYSIS: We independently inspected citations and selected studies. For included studies, we independently extracted data and appraised study quality. For binary outcomes we calculated the risk ratios (RRs) and their 95% confidence intervals. For continuous outcomes we calculated the mean differences (MDs) and their 95% confidence intervals. We pooled data using random-effects meta-analyses and assessed the quality of evidence, creating a 'Summary of findings' table using the GRADE approach. MAIN RESULTS: We identified eight randomised trials containing a total of 1073 participants with SMI and co-occurring substance misuse. Seven of these contributed useable data to the review. There was heterogeneity in trial design and measurement. Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone. Few trials compared risperidone with first-generation agents. Few trials examined participants with a dual diagnosis from the outset and most trials only contained separate analyses of subgroups with a dual diagnosis or were secondary data analyses of subgroups of people with a dual diagnosis from existing larger trials.For risperidone versus clozapine we found no clear differences between these two antipsychotics in the reduction of positive psychotic symptoms (1 randomised controlled trial (RCT), n = 36, mean difference (MD) 0.90, 95% CI -2.21 to 4.01, very low quality evidence), or reduction in cannabis use (1 RCT, n = 14, risk ratio (RR) 1.00, 95% CI 0.30 to 3.35, very low quality evidence), improvement in subjective well-being (1 RCT, n = 36, MD -6.00, 95% CI -14.82 to 2.82, very low quality evidence), numbers discontinuing medication (1 RCT, n = 36, RR 4.05, 95% CI 0.21 to 78.76, very low quality evidence), extrapyramidal side-effects (2 RCTs, n = 50, RR 2.71, 95% CI 0.30 to 24.08; I² = 0%, very low quality evidence), or leaving the study early (2 RCTs, n = 45, RR 0.49, 95% CI 0.10 to 2.51; I² = 34%, very low quality evidence). Clozapine was associated with lower levels of craving for cannabis (1 RCT, n = 28, MD 7.00, 95% CI 2.37 to 11.63, very low quality evidence).For risperidone versus olanzapine we found no clear differences in the reduction of positive psychotic symptoms (1 RCT, n = 37, MD -1.50, 95% CI -3.82 to 0.82, very low quality evidence), reduction in cannabis use (1 RCT, n = 41, MD 0.40, 95% CI -4.72 to 5.52, very low quality evidence), craving for cannabis (1 RCT, n = 41, MD 5.00, 95% CI -4.86 to 14.86, very low quality evidence), parkinsonism (1 RCT, n = 16, MD -0.08, 95% CI -1.21 to 1.05, very low quality evidence), or leaving the study early (2 RCT, n = 77, RR 0.68, 95% CI 0.34 to 1.35; I² = 0%, very low quality evidence).For risperidone versus perphenazine, we found no clear differences in the number of participants leaving the study early (1 RCT, n = 281, RR 1.05, 95% CI 0.92 to 1.20, low-quality evidence).For risperidone versus quetiapine, we found no clear differences in the number of participants leaving the study early (1 RCT, n = 294, RR 0.96, 95% CI 0.86 to 1.07, low-quality evidence).For risperidone versus ziprasidone, we found no clear differences in the number of participants leaving the study early (1 RCT, n = 240, RR 0.96, 95% CI 0.85 to 1.10, low-quality evidence).For many comparisons, important outcomes were missing; and no data were reported in any study for metabolic disturbances, global impression of illness severity, quality of life or mortality. AUTHORS' CONCLUSIONS: There is not sufficient good-quality evidence available to determine the effects of risperidone compared with other antipsychotics in people with a dual diagnosis. Few trials compared risperidone with first-generation agents, leading to limited applicability to settings where access to second-generation agents is limited, such as in low- and middle-income countries. Moreover, heterogeneity in trial design and measurement of outcomes precluded the use of many trials in our analyses. Future trials in this area need to be sufficiently powered but also need to conform to consistent methods in study population selection, use of measurement scales, definition of outcomes, and measures to counter risk of bias. Investigators should adhere to CONSORT guidelines in the reporting of results.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Transtornos Mentais/tratamento farmacológico
Risperidona/uso terapêutico
Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico
[Mh] Termos MeSH secundário: Benzodiazepinas/uso terapêutico
Clozapina/uso terapêutico
Diagnóstico Duplo (Psiquiatria)
Seres Humanos
Pacientes Desistentes do Tratamento/estatística & dados numéricos
Perfenazina/uso terapêutico
Piperazinas/uso terapêutico
Fumarato de Quetiapina/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Esquizofrenia/tratamento farmacológico
Transtornos Relacionados ao Uso de Substâncias/psicologia
Tiazóis/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Piperazines); 0 (Thiazoles); 12794-10-4 (Benzodiazepines); 2S3PL1B6UJ (Quetiapine Fumarate); 6UKA5VEJ6X (ziprasidone); FTA7XXY4EZ (Perphenazine); J60AR2IKIC (Clozapine); L6UH7ZF8HC (Risperidone); N7U69T4SZR (olanzapine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180123
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD011057.pub2


  5 / 84857 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28459904
[Au] Autor:Englander H; Weimer M; Solotaroff R; Nicolaidis C; Chan B; Velez C; Noice A; Hartnett T; Blackburn E; Barnes P; Korthuis PT
[Ad] Endereço:Oregon Health and Science University, Portland, OR; Central City Concern, Portland, OR.
[Ti] Título:Planning and Designing the Improving Addiction Care Team (IMPACT) for Hospitalized Adults with Substance Use Disorder.
[So] Source:J Hosp Med;12(5):339-342, 2017 05.
[Is] ISSN:1553-5606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:People with substance use disorders (SUD) have high rates of hospitalization and readmission, long lengths of stay, and skyrocketing healthcare costs. Yet, models for improving care are extremely limited. We performed a needs assessment and then convened academic and community partners, including a hospital, community SUD organizations, and Medicaid accountable care organizations, to design a care model for medically complex hospitalized patients with SUD. Needs assessment showed that 58% to 67% of participants who reported active substance use said they were interested in cutting back or quitting. Many reported interest in medication for addiction treatment (MAT). Participants had high rates of costly readmissions and longer than expected length of stay. Community stakeholders identified long wait times and lack of resources for medically complex patients as key barriers. We developed the Improving Addiction Care Team (IMPACT), which includes an inpatient addiction medicine consultation service, rapid-access pathways to posthospital SUD treatment, and a medically enhanced residential care model that integrates antibiotic infusion and residential addiction care. We developed a business case and secured funding from Medicaid and hospital payers. IMPACT provides one pathway for hospitals, payers, and communities to collaboratively address the SUD epidemic. Journal of Hospital Medicine 2017;12:339-342.
[Mh] Termos MeSH primário: Necessidades e Demandas de Serviços de Saúde/tendências
Hospitalização/tendências
Equipe de Assistência ao Paciente/tendências
Transtornos Relacionados ao Uso de Substâncias/terapia
[Mh] Termos MeSH secundário: Adulto
Registros Eletrônicos de Saúde/economia
Registros Eletrônicos de Saúde/tendências
Feminino
Necessidades e Demandas de Serviços de Saúde/economia
Hospitalização/economia
Seres Humanos
Masculino
Medicaid/economia
Medicaid/tendências
Equipe de Assistência ao Paciente/economia
Transtornos Relacionados ao Uso de Substâncias/economia
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.12788/jhm.2736


  6 / 84857 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29368473
[Au] Autor:Sharma ER; Shuler FD; Loudin S
[Ti] Título:Legal Aspects of Neonatal Abstinence Syndrome.
[So] Source:W V Med J;112(5):19, 2016 Sep-Oct.
[Is] ISSN:0043-3284
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Controle de Medicamentos e Entorpecentes/legislação & jurisprudência
Tempo de Internação/legislação & jurisprudência
Síndrome de Abstinência Neonatal
Admissão do Paciente/legislação & jurisprudência
Complicações na Gravidez
[Mh] Termos MeSH secundário: Feminino
Idade Gestacional
Seres Humanos
Recém-Nascido
Unidades de Terapia Intensiva Neonatal
Tempo de Internação/estatística & dados numéricos
Síndrome de Abstinência Neonatal/epidemiologia
Síndrome de Abstinência Neonatal/etiologia
Admissão do Paciente/estatística & dados numéricos
Gravidez
Complicações na Gravidez/epidemiologia
Complicações na Gravidez/etiologia
Prevalência
Psicotrópicos/efeitos adversos
Drogas Ilícitas/efeitos adversos
Drogas Ilícitas/legislação & jurisprudência
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
Transtornos Relacionados ao Uso de Substâncias/etiologia
West Virginia/epidemiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; EDITORIAL
[Nm] Nome de substância:
0 (Psychotropic Drugs); 0 (Street Drugs)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE


  7 / 84857 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386447
[Au] Autor:Mori T; Sawaguchi T
[Ad] Endereço:Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences.
[Ti] Título:[Underlying Mechanisms of Methamphetamine-Induced Self-Injurious Behavior and Lethal Effects in Mice].
[So] Source:Nihon Eiseigaku Zasshi;73(1):51-56, 2018.
[Is] ISSN:1882-6482
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Relatively high doses of psychostimulants induce neurotoxicity on the dopaminergic system and self-injurious behavior (SIB) in rodents. However the underlying neuronal mechanisms of SIB remains unclear. Dopamine receptor antagonists, N-methyl-D-aspartic acid (NMDA) receptor antagonists, Nitric Oxide Synthase (NOS) inhibitors and free radical scavengers significantly attenuate methamphetamine-induced SIB. These findings indicate that activation of dopamine as well as NMDA receptors followed by radical formation and oxidative stress, especially when mediated by NOS activation, is associated with methamphetamine-induced SIB. On the other hand, an increase in the incidence of polydrug abuse is a major problem worldwide. Coadministered methamphetamine and morphine induced lethality in more than 80% in mice, accompanied by an increase in the number of poly (ADP-ribose) polymerase (PARP)-immunoreactive cells in the heart, kidney and liver. The lethal effect and the increase in the incidence of rupture or PARP-immunoreactive cells induced by the coadministration of methamphetamine and morphine were significantly attenuated by pretreatment with a phospholipase A2 inhibitor or a radical scavenger, or by cooling of body from 30 to 90 min after drug administration. These results suggest that free radicals play an important role in the increased lethality induced by the coadministration of methamphetamine and morphine. Therefore, free radical scavengers and cooling are beneficial for preventing death that is induced by the coadministration of methamphetamine and morphine. These findings may help us better understand for masochistic behavior, which is a clinical phenomenon on SIB, as well as polydrug-abuse-induced acute toxicity.
[Mh] Termos MeSH primário: Estimulantes do Sistema Nervoso Central/efeitos adversos
Estimulantes do Sistema Nervoso Central/toxicidade
Metanfetamina/efeitos adversos
Metanfetamina/toxicidade
Comportamento Autodestrutivo/induzido quimicamente
[Mh] Termos MeSH secundário: Animais
Antagonistas de Dopamina/farmacologia
Antagonistas de Dopamina/uso terapêutico
Neurônios Dopaminérgicos/efeitos dos fármacos
Relação Dose-Resposta a Droga
Interações Medicamentosas
Depuradores de Radicais Livres/farmacologia
Depuradores de Radicais Livres/uso terapêutico
Radicais Livres/efeitos adversos
Radicais Livres/toxicidade
Seres Humanos
Dose Letal Mediana
Metanfetamina/administração & dosagem
Morfina/administração & dosagem
Morfina/efeitos adversos
Morfina/toxicidade
Receptores de N-Metil-D-Aspartato/antagonistas & inibidores
Comportamento Autodestrutivo/etiologia
Transtornos Relacionados ao Uso de Substâncias
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 0 (Dopamine Antagonists); 0 (Free Radical Scavengers); 0 (Free Radicals); 0 (Receptors, N-Methyl-D-Aspartate); 44RAL3456C (Methamphetamine); 76I7G6D29C (Morphine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1265/jjh.73.51


  8 / 84857 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29206947
[Au] Autor:DeRigne LA; Burki A; Stoddard-Dare P
[Ad] Endereço:School of Social Work, Florida Atlantic University, 777 Glades Road, Boca Raton, FL 33431; Life of Purpose Treatment Center, Boca Raton, FL. Cleveland State University.
[Ti] Título:Academic Disruption and Substance Use Disorders: University-Based Treatment Facilities.
[So] Source:Health Soc Work;41(3):201-204, 2016 Aug 01.
[Is] ISSN:0360-7283
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Estudantes/psicologia
Centros de Tratamento de Abuso de Substâncias/organização & administração
Transtornos Relacionados ao Uso de Substâncias/terapia
Universidades
[Mh] Termos MeSH secundário: Adolescente
Feminino
Seres Humanos
Masculino
Modelos Organizacionais
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1093/hsw/hlw020


  9 / 84857 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29466163
[Au] Autor:Lembke A; Papac J; Humphreys K
[Ad] Endereço:From the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford (A.L., J.P., K.H.), and the Veterans Affairs Palo Alto Health Care System (K.H.) - both in California.
[Ti] Título:Our Other Prescription Drug Problem.
[So] Source:N Engl J Med;378(8):693-695, 2018 Feb 22.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Benzodiazepinas/uso terapêutico
Uso Excessivo de Produtos e Serviços de Saúde/tendências
Uso Indevido de Medicamentos sob Prescrição/tendências
Transtornos Relacionados ao Uso de Substâncias
[Mh] Termos MeSH secundário: Seres Humanos
Uso Excessivo de Produtos e Serviços de Saúde/prevenção & controle
Transtornos Relacionados ao Uso de Substâncias/mortalidade
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
12794-10-4 (Benzodiazepines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMp1715050


  10 / 84857 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29360862
[Au] Autor:Davison KM; Holloway C; Gondara L; Hatcher AS
[Ad] Endereço:School of Nursing, University of British Columbia, Vancouver, British Columbia, Canada.
[Ti] Título:Independent associations and effect modification between lifetime substance use and recent mood disorder diagnosis with household food insecurity.
[So] Source:PLoS One;13(1):e0191072, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Poor mental health and substance use are associated with food insecurity, however, their potential combined effects have not been studied. This study explored independent associations and effect modification between lifetime substance use and mood disorder in relation to food insecurity. Poisson regression analysis of data from British Columbia respondents (n = 13,450; 12 years+) in the 2007/08 Canadian Community Health Survey was conducted. Measures included The Household Food Security Survey Module (7.3% food insecure), recent diagnosis of a mood disorder (self-reported; 9.5%), lifetime use of cannabis, cocaine/crack, ecstasy, hallucinogens, and speed, any lifetime substance use, sociodemographic covariates, and the interaction terms of mood disorder by substance. For those with recent diagnosis of a mood disorder the prevalence of lifetime substance use ranged between 1.2 to 5.7% and were significantly higher than those without recent mood disorder diagnosis or lifetime use of substances (p's < 0.05). For respondents with a recent mood disorder diagnosis or who used cannabis, food insecurity prevalence was higher compared to the general sample (p < 0.001); prevalence was lower for cocaine/crack use (p < 0.05). Significant effect modification was found between mood disorder with cannabis, ecstasy, hallucinogen and any substance use over the lifetime (PRs 0.51 to 0.64, p's 0.022 to 0.001). Independent associations were found for cocaine/crack and speed use (PRs 1.68, p's < 0.001) and mood disorder (PRs 2.02, p's < 0.001). Based on these findings and the existing literature, future study about coping and resilience in the context of substance use, mental health, and food insecurity may lead to the development of relevant interventions aimed at mental well-being and food security.
[Mh] Termos MeSH primário: Abastecimento de Alimentos
Transtornos do Humor/complicações
Transtornos Relacionados ao Uso de Substâncias/complicações
[Mh] Termos MeSH secundário: Colúmbia Britânica
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191072



página 1 de 8486 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde